China Resources Pharma reports mixed half-year 2025 results

China Resources Pharmaceutical Group Limited reported total revenue of 131,866.8 million yuan for the first half of 2025, a 2.5% increase from the same period last year. Pharmaceutical manufacturing, distribution, and retail contributed 16.6%, 79.2%, and 4.2% of total revenue, respectively. Gross profit rose by 2.8% to 21,509.6 million yuan, maintaining a gross profit margin of 16.3%.

Despite revenue growth, the Group’s net profit decreased by 8.8% to 5,053.6 million yuan, with profit attributable to equity shareholders falling 20.3% to 2,077.3 million yuan. This decline was partially attributed to one-off items like impairment of associates. Basic earnings per share were 0.33 yuan, down from 0.41 yuan in the first half of 2024. The board declared an interim dividend of 0.072 yuan per share.

The pharmaceutical manufacturing segment saw a 4.3% revenue increase to 24,808.3 million yuan, with growth across Traditional Chinese Medicine (TCM), biopharmaceuticals, and nutraceuticals. The distribution business revenue grew by 2.3% to 108,329.7 million yuan, while retail revenue increased by 11.4% to 5,514.6 million yuan, boosted by rapid growth in the Direct To Patient (DTP) business.